Ventyx Biosciences (NASDAQ:VTYX) Releases Earnings Results, Beats Expectations By $0.07 EPS

Ventyx Biosciences (NASDAQ:VTYX – Get Rating) posted its earnings results on Thursday. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.07, MarketWatch Earnings reports.

VTYX opened at $14.91 on Friday. The company’s 50 day simple moving average is $13.44 and its two-hundred day simple moving average is $15.42. Ventyx Biosciences has a 1-year low of $9.50 and a 1-year high of $26.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. Bank of America Corp DE purchased a new position in Ventyx Biosciences in the 4th quarter worth approximately $932,000. Citigroup Inc. purchased a new stake in shares of Ventyx Biosciences during the 4th quarter valued at approximately $56,000. JPMorgan Chase & Co. purchased a new stake in shares of Ventyx Biosciences during the 4th quarter valued at approximately $1,257,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Ventyx Biosciences during the 4th quarter valued at approximately $1,417,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Ventyx Biosciences during the 4th quarter valued at approximately $3,724,000. 62.30% of the stock is currently owned by institutional investors and hedge funds.

VTYX has been the topic of several research analyst reports. Oppenheimer initiated coverage on Ventyx Biosciences in a report on Tuesday, February 1st. They issued an “outperform” rating and a $30.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Ventyx Biosciences in a report on Thursday, March 31st. They issued a “buy” rating and a $30.00 price objective on the stock. Credit Suisse Group initiated coverage on Ventyx Biosciences in a report on Monday, May 9th. They issued an “outperform” rating and a $53.00 price objective on the stock. Zacks Investment Research upgraded Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, March 26th. Finally, Canaccord Genuity Group initiated coverage on Ventyx Biosciences in a report on Thursday, March 31st. They issued a “buy” rating on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $40.50.

Ventyx Biosciences Company Profile (Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.

Read More